A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer

NCT07543471 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

387

Enrollment

INDUSTRY

Sponsor class

Conditions

mCRC

Interventions

DRUG: Cetuximab
DRUG: mFOLFOX6

Sponsor

Shanghai Henlius Biotech